Cargando…
Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy
The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immun...
Autores principales: | Yang, Yan, Yang, Zheng, Yang, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8297387/ https://www.ncbi.nlm.nih.gov/pubmed/34305918 http://dx.doi.org/10.3389/fimmu.2021.686031 |
Ejemplares similares
-
Current landscape and future directions of bispecific antibodies in cancer immunotherapy
por: Wei, Jing, et al.
Publicado: (2022) -
Dual blockade of CD47 and CD24 signaling using a novel bispecific antibody fusion protein enhances macrophage immunotherapy
por: Yang, Yun, et al.
Publicado: (2023) -
Tumor-Directed Blockade of CD47 with Bispecific Antibodies Induces Adaptive Antitumor Immunity
por: Dheilly, Elie, et al.
Publicado: (2018) -
Bispecific antibodies targeting CTLA-4: game-changer troopers in cancer immunotherapy
por: Farhangnia, Pooya, et al.
Publicado: (2023) -
Potential New Cancer Immunotherapy: Anti-CD47-SIRPα Antibodies
por: Lu, Quansheng, et al.
Publicado: (2020)